NIH Announcement of Pivotal Phase III Intranasal Influenza Vaccine Trial Success
N/AThe National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) announced that, based on an initial analysis of a pivotal Phase III trial, AvironÃs (pronounced Av-uh-ron; Nasdaq: AVIR) intranasal cold adapted influenza vaccine prevented culture-confirmed influenza in nearly all of the children who received it.